Last reviewed · How we verify
Crushed ticagrelor, morphine,naloxone
This combination uses ticagrelor to inhibit platelet aggregation, morphine for pain relief and anxiolysis, and naloxone as an opioid antagonist to reduce morphine-related adverse effects.
This combination uses ticagrelor to inhibit platelet aggregation, morphine for pain relief and anxiolysis, and naloxone as an opioid antagonist to reduce morphine-related adverse effects. Used for Acute coronary syndrome with pain management, Post-acute cardiac event analgesia.
At a glance
| Generic name | Crushed ticagrelor, morphine,naloxone |
|---|---|
| Also known as | Brilique |
| Sponsor | Collegium Medicum w Bydgoszczy |
| Drug class | Antiplatelet agent + opioid + opioid antagonist combination |
| Target | P2Y12 receptor (ticagrelor); mu opioid receptor (morphine); opioid receptors (naloxone antagonism) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor is a P2Y12 platelet receptor antagonist that prevents thrombotic events. Morphine is an opioid agonist providing analgesia and anxiolysis. Naloxone is an opioid antagonist included to mitigate morphine's respiratory depression and other opioid-related side effects while maintaining analgesic efficacy. This combination appears designed for acute coronary syndrome or post-acute cardiac care with pain management.
Approved indications
- Acute coronary syndrome with pain management
- Post-acute cardiac event analgesia
Common side effects
- Bleeding (ticagrelor)
- Bradycardia (ticagrelor)
- Dyspnea (ticagrelor)
- Nausea/vomiting (morphine)
- Constipation (morphine)
- Dizziness (morphine)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: